- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Enrollment change: Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (clinicaltrials.gov) - Feb 18, 2016 P2, N=1, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2016 | Trial primary completion date: Jul 2018 --> Feb 2018 Recruiting --> Active, not recruiting | N=32 --> 1
- |||||||||| Trial primary completion date, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Feb 17, 2016
P2, N=20, Active, not recruiting, Trial primary completion date: Oct 2016 --> Jul 2017 Trial primary completion date: Dec 2015 --> Jun 2016
- |||||||||| telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 17, 2016 P1, N=124, Active, not recruiting, Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Dec 2015 --> Apr 2016
- |||||||||| Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Combination therapy, Metastases: MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 16, 2016 P1, N=34, Recruiting, Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Jun 2016 --> Dec 2016
- |||||||||| Enrollment open, Trial initiation date, Trial primary completion date: Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma (clinicaltrials.gov) - Feb 12, 2016
P2, N=30, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018
- |||||||||| Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change, Combination therapy, Metastases: Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2016 P2, N=181, Active, not recruiting, Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Dec 2015 | Trial primary completion date: Jan 2017 --> Jan 2018 Recruiting --> Active, not recruiting | N=240 --> 181
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Feb 8, 2016 P1/2, N=78, Recruiting, N=40 --> 3 | Recruiting --> Terminated; Recruitment difficulties Not yet recruiting --> Recruiting
- |||||||||| EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Feb 4, 2016 P1, N=30, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Jul 2016
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Feb 3, 2016 P3, N=650, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 2, 2016 P1, N=18, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Jan 2017
- |||||||||| futuximab/modotuximab (S95026) / Servier
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Feb 1, 2016 P1/2, N=50, Not yet recruiting, Phase classification: P2/3 --> P3 | N=256 --> 175 | Trial primary completion date: May 2017 --> Sep 2017 Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018
- |||||||||| Zolinza (vorinostat) / Merck (MSD), Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Phase classification: Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I (clinicaltrials.gov) - Feb 1, 2016 P1/2, N=50, Recruiting, Initiation date: Nov 2015 --> Mar 2016 | Trial primary completion date: Nov 2017 --> May 2018 Phase classification: P2 --> P1/2
- |||||||||| Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Jan 30, 2016
P2, N=40, Recruiting, N=360 --> 44 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Dec 2015; Low or poor accrual Trial primary completion date: Oct 2015 --> Dec 2016
- |||||||||| Vectibix (panitumumab) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment (clinicaltrials.gov) - Jan 25, 2016 P1, N=74, Completed, Not yet recruiting --> Recruiting Recruiting --> Completed | N=50 --> 74 | Trial primary completion date: Dec 2013 --> May 2013
- |||||||||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 25, 2016 P1, N=21, Active, not recruiting, Trial primary completion date: Apr 2015 --> Apr 2017 Recruiting --> Active, not recruiting | N=15 --> 21 | Trial primary completion date: Apr 2016 --> Jan 2016
|